Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Upcoming Live Events
Covered Companies
Covered Companies
Series
CEO Connect
Featuring: Autonomix Medical
May 13, 2025
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market
What This Means
Featuring: CNS Pharmaceuticals
May 13, 2025
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)
KOL Connect
Featuring: Veru
May 8, 2025
Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru
What This Means
Featuring: GRI Bio
May 8, 2025
Marc Hertz, President and CEO of GRI Bio discusses Interim Biomarker Data Demonstrating Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
What This Means
Featuring: Autonomix
May 1, 2025
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated
Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025
What This Means
Featuring: SENTI Bio
May 1, 2025
Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
Past Events
Past Events
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact